[go: up one dir, main page]

AR040038A1 - Composicion analgesica que comprende un agonista alfa-adrenergico con una actividad agonista alfa-2a minima y uso de un agonista alfa-adrenergico y un antagonista selectivo alfa-2a para preparar composiciones farmaceuticas para aliviar el dolor - Google Patents

Composicion analgesica que comprende un agonista alfa-adrenergico con una actividad agonista alfa-2a minima y uso de un agonista alfa-adrenergico y un antagonista selectivo alfa-2a para preparar composiciones farmaceuticas para aliviar el dolor

Info

Publication number
AR040038A1
AR040038A1 ARP030101753A ARP030101753A AR040038A1 AR 040038 A1 AR040038 A1 AR 040038A1 AR P030101753 A ARP030101753 A AR P030101753A AR P030101753 A ARP030101753 A AR P030101753A AR 040038 A1 AR040038 A1 AR 040038A1
Authority
AR
Argentina
Prior art keywords
alfa
alpha
agonist
adrenergic agonist
adrenergic
Prior art date
Application number
ARP030101753A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR040038A1 publication Critical patent/AR040038A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Composición analgésica que comprende un agonista alfa-adrenérgico con una actividad agonista alfa-2A mínima, dicho agonista tiene la capacidad de producir analgesia periférica sin sedación concomitante. Uso de un agonista alfa-adrenérgico y un antagonista selectivo alfa-2A para preparar una primera y una segunda composición farmacéutica de aplicación en un método para aliviar el dolor en un mamífero mediante la administración a dicho mamífero la primera composición farmacéutica que comprende una cantidad efectiva del agonista alfa-adrenérgico y, eventualmente, la segunda composición farmacéutica que comprende una cantidad efectiva del antagonista selectivo alfa-2A. Se propone lograr el alivio duradero del dolor crónico en un mamífero activando en el mismo un receptor alfa-adrenérgico analgésico en ausencia de la activación del receptor alfa- 2A durante un periodo de al menos tres días, de manera tal que el alivio del dolor crónico se mantenga en la ausencia de la activación continuada de dicho receptor. El receptor alfa-adrenérgico analgésico puede ser, por ejemplo, el receptor alfa- 2B.
ARP030101753A 2002-05-21 2003-05-20 Composicion analgesica que comprende un agonista alfa-adrenergico con una actividad agonista alfa-2a minima y uso de un agonista alfa-adrenergico y un antagonista selectivo alfa-2a para preparar composiciones farmaceuticas para aliviar el dolor AR040038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/153,154 US7345065B2 (en) 2002-05-21 2002-05-21 Methods and compositions for alleviating pain

Publications (1)

Publication Number Publication Date
AR040038A1 true AR040038A1 (es) 2005-03-09

Family

ID=29582080

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101753A AR040038A1 (es) 2002-05-21 2003-05-20 Composicion analgesica que comprende un agonista alfa-adrenergico con una actividad agonista alfa-2a minima y uso de un agonista alfa-adrenergico y un antagonista selectivo alfa-2a para preparar composiciones farmaceuticas para aliviar el dolor

Country Status (17)

Country Link
US (2) US7345065B2 (es)
EP (2) EP1507536A2 (es)
JP (3) JP2005538952A (es)
KR (1) KR101114184B1 (es)
CN (1) CN1671391B (es)
AR (1) AR040038A1 (es)
AU (1) AU2003231142B2 (es)
BR (1) BR0311325A (es)
CA (1) CA2486716C (es)
IL (2) IL165279A0 (es)
MX (1) MXPA04011547A (es)
NO (1) NO20045055L (es)
PL (1) PL374147A1 (es)
RU (1) RU2329062C2 (es)
TW (1) TWI314054B (es)
WO (1) WO2003099289A2 (es)
ZA (1) ZA200409332B (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6559186B1 (en) 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
KR100764348B1 (ko) * 2000-12-09 2007-10-08 주식회사 하이닉스반도체 디지털/아날로그 컨버터
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7358269B2 (en) * 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20060293359A1 (en) * 2003-06-25 2006-12-28 Allergan, Inc. Methods and compositions for the treatment of diabetes
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US8708993B1 (en) * 2003-10-15 2014-04-29 Physician Technologies, Inc. Infusion catheter procedure and system
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
JP2008514601A (ja) * 2004-09-24 2008-05-08 アラーガン、インコーポレイテッド 特異的α２アドレナリン作動剤としての４−（フェニルメチルおよび置換フェニルメチル）−イミダゾール−２−チオン
EP1791833A2 (en) * 2004-09-24 2007-06-06 Allergan, Inc. 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
AU2005290013A1 (en) * 2004-09-28 2006-04-06 Allergan, Inc. Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
MX2007014219A (es) * 2005-05-13 2008-04-08 Medimush As Productos alimenticios o forrajeros que comprenden material fungico.
US8026266B2 (en) * 2005-11-08 2011-09-27 Arcion Therapeutics, Inc. Treatment of length dependent neuropathy
CN101309704B (zh) 2005-11-14 2012-10-10 礼纳特神经系统科学公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
US8536445B2 (en) * 2006-06-02 2013-09-17 Emcore Solar Power, Inc. Inverted metamorphic multijunction solar cells
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080102097A1 (en) * 2006-10-31 2008-05-01 Zanella John M Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
CA2673616A1 (en) * 2006-12-22 2008-07-03 Allergan, Inc. Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
WO2008079727A2 (en) * 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20120083508A1 (en) 2006-12-22 2012-04-05 Allergan, Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US20110160265A1 (en) * 2007-10-18 2011-06-30 Luhrs Lauren M B Method of treating motor disorders with alpha-2b adrenergic receptor agonists
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2009052072A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
DK2252290T3 (en) * 2008-02-15 2018-03-05 Bone Therapeutics Sa PHARMACEUTICAL COMPOSITION FOR USE FOR TREATMENT AND / OR PREVENTION OF OSTEOARTICULAR DISEASES
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
US20090263489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US9132119B2 (en) * 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8722079B2 (en) * 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US9610243B2 (en) 2008-04-18 2017-04-04 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
US9034910B2 (en) 2008-06-09 2015-05-19 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions
WO2009152053A1 (en) 2008-06-09 2009-12-17 Allergan, Inc. Methods of treating alpha adrenergic mediated conditions using imidazoline derivates
ES2665293T3 (es) 2008-06-09 2018-04-25 Allergan, Inc. Compuesto para tratar estados con mediación alfa-adrenérgica
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
SI2320911T1 (sl) 2008-08-01 2014-12-31 Eye Therapies Llc Vazokonstrikcijski sestavki in metode uporabe
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
EP2165706A1 (en) * 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010148519A1 (en) * 2009-06-25 2010-12-29 Queen's University At Kingston Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist
US8617583B2 (en) * 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
EP2459542B1 (en) * 2009-07-30 2014-10-29 Allergan, Inc. Substituted N-benzyl-4,5-dihydrooxazol-2-amines useful as selective alpha 2B/2C receptor agonists
US8231891B2 (en) * 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
EP2470181A1 (en) 2009-08-26 2012-07-04 Allergan, Inc. Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
AU2010288194B2 (en) 2009-08-28 2013-08-29 Teva Pharmaceuticals International Gmbh Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
WO2011075621A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
CN101837000B (zh) * 2010-03-16 2011-11-09 云南大学 2-氟-β-D-糖苷在制备治疗神经源性疼痛的药物中的用途
DK2552449T3 (en) 2010-03-26 2017-06-19 Galderma Res & Dev COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
EP2552448B1 (en) 2010-03-26 2019-04-24 Galderma Research & Development Improved compositions comprising brimonidine for safe and effective treatment of telangiectasia
GB201013573D0 (en) * 2010-08-12 2010-09-29 Ucl Business Plc Treatment
TR201809456T4 (tr) 2010-08-16 2018-07-23 Allergan Inc Alfa-2b adrenerjik reseptör agonistleri olan düzenleyici t hücrelerini aktifleştirme metodu.
MX354697B (es) 2010-10-21 2018-03-15 Galderma Sa Composiciones de gel de brimonidina y métodos de uso.
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
CN103748111B (zh) 2011-05-20 2018-04-27 奥尔德生物控股有限责任公司 抗cgrp组合物及其用途
KR101965461B1 (ko) 2011-05-20 2019-04-04 앨더바이오 홀딩스 엘엘씨 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
JP2014530846A (ja) 2011-10-19 2014-11-20 ガルデルマ ソシエテ アノニム ホスホジエステラーゼ５型阻害薬の全身使用に伴う顔面潮紅の軽減方法
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
EP2821072A1 (en) 2013-07-01 2015-01-07 Ecole Polytechnique Fédérale de Lausanne (EPFL) Pharmacological stimulation to facilitate and restore standing and walking functions in spinal cord disorders
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
BR112020018192A2 (pt) 2019-01-08 2021-08-24 H. Lundbeck A/S Tratamento agudo e tratamento rápido de dor de cabeça com o uso de anticorpos anti-cgrp
US11185532B2 (en) 2019-05-01 2021-11-30 Clexio Biosciences Ltd. Methods of treating pruritus
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021410A (en) * 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
JP3805360B2 (ja) * 1994-01-24 2006-08-02 アラーガン、インコーポレイテッド α▲下２Ａ▼アドレナリン受容体作動剤としての芳香族２−アミノ−イミダゾール誘導体
US6087361A (en) * 1995-05-12 2000-07-11 Allergan Sales, Inc. Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects
FR2740040B1 (fr) * 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
IL136303A (en) * 1997-11-24 2004-02-08 Procter & Gamble History -5 (-2 Imidazolinylamino) - Banimidazole, preparation and use as an α-adororeceptor agonists
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
PL341009A1 (en) 1997-12-04 2001-03-12 Allergan Sales Substitute derivatives of imidazole exhibiting agonist-like activity in respect to adrenergic alpha 2b or 2b/2c receptors
HK1048259B (en) * 1998-10-20 2005-06-03 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
TWI283669B (en) 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6545182B2 (en) 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain

Also Published As

Publication number Publication date
BR0311325A (pt) 2005-02-22
MXPA04011547A (es) 2005-02-14
EP2351561A2 (en) 2011-08-03
US20040132824A1 (en) 2004-07-08
JP2005538952A (ja) 2005-12-22
CN1671391B (zh) 2013-03-27
CA2486716C (en) 2014-06-03
IL165279A (en) 2011-07-31
JP5457981B2 (ja) 2014-04-02
KR101114184B1 (ko) 2012-08-30
CN1671391A (zh) 2005-09-21
WO2003099289A2 (en) 2003-12-04
NO20045055L (no) 2005-02-17
JP5673973B2 (ja) 2015-02-18
AU2003231142A1 (en) 2003-12-12
WO2003099289A3 (en) 2004-03-18
EP1507536A2 (en) 2005-02-23
US7345065B2 (en) 2008-03-18
KR20050010836A (ko) 2005-01-28
CA2486716A1 (en) 2003-12-04
RU2329062C2 (ru) 2008-07-20
AU2003231142B2 (en) 2009-04-23
TW200404549A (en) 2004-04-01
TWI314054B (en) 2009-09-01
JP2010265316A (ja) 2010-11-25
JP2013075925A (ja) 2013-04-25
EP2351561A3 (en) 2012-02-01
PL374147A1 (en) 2005-10-03
US20030229088A1 (en) 2003-12-11
RU2004134560A (ru) 2005-08-10
ZA200409332B (en) 2005-06-29
IL165279A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
AR040038A1 (es) Composicion analgesica que comprende un agonista alfa-adrenergico con una actividad agonista alfa-2a minima y uso de un agonista alfa-adrenergico y un antagonista selectivo alfa-2a para preparar composiciones farmaceuticas para aliviar el dolor
WO2001082914A3 (en) Topical anesthetic/opioid formulations and uses thereof
WO2004056305A3 (en) Administration of capsaicinoids
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
AR042937A2 (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
TNSN07209A1 (en) Dosage regimen of an s1p receptor agonist
AR061985A1 (es) Composiciones farmaceuticas orales, particularmente aptas para aliviar resfrios, tos, gripe, fiebre, jaqueca, dolor, dolor corporal, migraña o sintomas alergicos
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
DK0954314T3 (da) Doseringsformer til bedring af mandlig erektionsdefekt
AR022723A1 (es) Compuestos analgesicos que comprenden compuestos antiepilepticos y metodos para usarlas
AR033342A1 (es) Una composicion otica topica o intranasal para tratar el dolor otico y el uso topico de agonistas de opioides kapa para tratar el dolor otico
ID27503A (id) Tts yang mengandung antioksidan
AR026916A1 (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
AR049934A1 (es) Nuevo uso de meloxicam en medicina veterinaria
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
BRPI0912112B8 (pt) composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
AR030957A1 (es) Composiciones de analgesico y glucosamina
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
MY141012A (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
MX9701477A (es) Composicion para aliviar el dolor, que contiene un analgesico no narcotico y un mejorador de analgesia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal